PeptideJournal
FAQ10 min read

Can Peptides Help with Scars?

Scars are the body's imperfect solution to a wound. Instead of rebuilding the original tissue with its organized collagen architecture, blood vessels, hair follicles, and sweat glands, the body patches the gap with dense, disorganized collagen fibers — functional enough to close the wound, but

Scars are the body's imperfect solution to a wound. Instead of rebuilding the original tissue with its organized collagen architecture, blood vessels, hair follicles, and sweat glands, the body patches the gap with dense, disorganized collagen fibers — functional enough to close the wound, but visually and structurally different from normal skin.

The emerging question in dermatology and regenerative medicine: can peptides shift this process? Can they push wound healing toward regeneration (rebuilding tissue that looks and functions like the original) rather than repair (filling the gap with scar tissue)?

The preclinical evidence is genuinely promising. The clinical evidence is still catching up.

Table of Contents

How Scars Form: The Biology You Need to Know

Wound healing proceeds through four overlapping phases [1]:

1. Hemostasis (minutes to hours). Platelets aggregate, fibrin forms a clot, bleeding stops. Growth factors are released that recruit immune cells.

2. Inflammation (hours to days). Neutrophils and macrophages clean up debris and fight infection. Inflammatory cytokines signal fibroblasts to start mobilizing.

3. Proliferation (days to weeks). Fibroblasts migrate into the wound, producing new collagen (primarily Type III initially), new blood vessels form (angiogenesis), and granulation tissue fills the wound bed. Keratinocytes migrate across the surface to close the wound.

4. Remodeling (weeks to months/years). The initial disorganized Type III collagen is gradually replaced by stronger, more organized Type I collagen. This phase determines the final scar quality. It can last 6-18 months.

Scars form because the remodeling phase never fully restores the original tissue architecture. Normal skin has basket-weave collagen organization. Scar tissue has parallel, densely packed collagen fibers. The result: scar tissue has only about 80% of the tensile strength of normal skin and lacks hair follicles, sebaceous glands, and normal pigmentation [2].

The key insight for peptide therapy: if you can modulate the proliferation and remodeling phases — improve collagen organization, regulate inflammation, support angiogenesis, and reduce excess collagen deposition — you can potentially improve scar outcomes.

Types of Scars and Why They Matter for Treatment

Different scar types respond differently to interventions:

Scar TypeCharacteristicsPeptide Relevance
Flat/NormalPale, flat, mature scarPeptides may improve texture and color
HypertrophicRaised, red, stays within wound bordersPeptides targeting TGF-beta and collagen regulation
KeloidGrows beyond wound borders, doesn't regressMost challenging; TGF-beta modulation research
AtrophicDepressed, indented (acne scars, pockmarks)Peptides stimulating collagen production
ContractureTight, restricting movement (burn scars)Peptides supporting tissue remodeling

Peptides with Scar-Relevant Research

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex)

GHK-Cu has the strongest evidence base for scar modulation among topical peptides. This naturally occurring tripeptide-copper complex was first identified by Dr. Loren Pickart in human plasma, where its concentration declines from about 200 ng/mL at age 20 to 80 ng/mL by age 60 [3].

How GHK-Cu affects scarring:

  • Stimulates collagen synthesis (Types I and III) and elastin production
  • Promotes angiogenesis — new blood vessels bring oxygen and nutrients to healing tissue
  • Recruits fibroblasts and stimulates their activity
  • Regulates TGF-beta signaling — this is the key anti-scarring mechanism. TGF-beta1 drives excessive collagen deposition (scarring), while TGF-beta3 is associated with reduced scarring. GHK-Cu appears to modulate this balance toward TGF-beta3 [4]
  • Activates genes involved in tissue remodeling while suppressing genes associated with fibrosis
  • Produces anti-inflammatory effects that reduce the excessive inflammation driving scar formation

Gene profiling studies revealed that GHK affects over 4,000 human genes — many related to tissue remodeling, anti-inflammatory responses, and antioxidant activity [5].

BPC-157

BPC-157 has been studied extensively in animal wound healing models. Key findings for scar-relevant outcomes:

  • In rat skin incision wounds, BPC-157 significantly increased granulation tissue formation, angiogenesis, and collagen production compared to controls [6]
  • BPC-157 accelerated collagen organization and stimulated expression of the egr-1 gene and its repressor nab2 — a feedback loop that may prevent uncontrolled tissue growth
  • Promoted healing in various wound types: incisional, excisional, burn wounds, and diabetic ulcers
  • Increased blood vessel formation through VEGF upregulation, addressing one of the key bottlenecks in wound healing

The limitation: Nearly all BPC-157 wound healing research is in animals. While the results are consistent and the biological mechanisms are well-characterized, translation to human scar outcomes hasn't been validated in clinical trials.

TB-500 (Thymosin Beta-4)

TB-500 is a synthetic fragment of thymosin beta-4, which regulates actin polymerization — a process central to cell migration and tissue repair. For scarring, TB-500's relevant properties include:

  • Promoting cell migration into wound sites
  • Reducing inflammation
  • Supporting angiogenesis
  • A proposed three-phase model suggests TB-500 works in the intermediate phase of healing (days 3-14), facilitating the cell migration that precedes collagen deposition [7]

KPV

KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) with potent anti-inflammatory properties. For scarring, its primary contribution is reducing the excessive inflammation that drives hypertrophic scar and keloid formation. Less inflammation during the proliferative phase generally means better scar outcomes.

Topical Skincare Peptides for Scarring

Several commercially available skincare peptides have scar-relevant properties:

Matrixyl (Palmitoyl Pentapeptide-4)

Matrixyl signals fibroblasts to produce collagen through a matrikine (extracellular matrix fragment) signaling mechanism. For atrophic scars (indented scars, acne scars), stimulating collagen production in the scar bed can improve texture and depth. Clinical studies show Matrixyl increases collagen synthesis by up to 117% in treated skin.

Argireline (Acetyl Hexapeptide-3)

Argireline reduces muscle contraction by inhibiting SNARE complex formation. While not directly scar-related, it may help with scars in expression-line areas where repeated muscle movement creates tension on healing tissue.

Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7

This combination (marketed as Matrixyl 3000) stimulates collagen production (tripeptide-1) while reducing inflammation (tetrapeptide-7). The dual action is relevant for scars where both collagen rebuilding and inflammation control are needed.

Copper Peptide Serums

Topical GHK-Cu serums (typically 0.1-1% concentration) are the most directly scar-relevant skincare peptide products. Applied twice daily to healing or mature scars, they support the remodeling phase that determines final scar quality.

Injectable Peptides and Scar Research

The injectable peptides most discussed for scar improvement are BPC-157 and TB-500. The rationale for injection rather than topical application: systemic or local injection delivers higher concentrations directly to the tissue, bypassing the barrier function of the skin (which limits how much topical peptide actually reaches the dermis).

A small retrospective study (Lee and Padgett, 2021) examined 16 patients receiving intra-articular injections of BPC-157 alone or BPC-157 plus thymosin beta-4 for knee injuries. While the study focused on pain and function rather than scar outcomes, 14 of 16 patients reported significant improvement [8]. The study's limitations — small size, no controls, no scar-specific outcomes — mean it contributes more to the safety picture than to scar evidence.

For burn scars, surgical scars, and keloids, injectable peptide therapy remains experimental. No peptide has FDA approval for scar treatment, and large clinical trials are needed.

The Collagen Remodeling Question

The distinction between collagen production and collagen organization is critical for scar outcomes.

Many peptides stimulate collagen production. That's helpful for atrophic scars (where you need more collagen to fill the depression) but potentially counterproductive for hypertrophic scars and keloids (where the problem is too much collagen).

What matters for scar quality is collagen organization — how the fibers are arranged, the ratio of Type I to Type III collagen, and the balance between matrix metalloproteinases (MMPs, which break down collagen) and tissue inhibitors of metalloproteinases (TIMPs, which prevent collagen breakdown) [9].

GHK-Cu stands out here because it doesn't just increase collagen production — it modulates the entire remodeling process, including MMP/TIMP balance and TGF-beta signaling. This suggests it could improve scar quality rather than simply adding more collagen.

Peptides for Keloids and Hypertrophic Scars

Keloids and hypertrophic scars are driven by excessive collagen deposition, often triggered by prolonged inflammation and dysregulated TGF-beta signaling. Treatment is challenging — these scars resist standard therapies and have high recurrence rates.

Peptide-based approaches under investigation:

  • GHK-Cu — By modulating TGF-beta balance (reducing TGF-beta1, supporting TGF-beta3), GHK-Cu may reduce the fibrotic drive that creates these scars
  • Anti-TGF-beta peptides — Experimental peptides designed to block TGF-beta1 signaling specifically at the wound site
  • Decorin-derived peptides — Decorin is a proteoglycan that inhibits TGF-beta. Peptides mimicking decorin's anti-fibrotic properties are in early research
  • LL-37 fragments — Antimicrobial peptides that may also modulate the inflammatory phase of wound healing [10]

What the Research Does and Doesn't Support

What's supported:

  • GHK-Cu improves wound healing quality in laboratory and some clinical settings
  • BPC-157 accelerates wound healing in animal models with improved collagen organization
  • TB-500 promotes cell migration and reduces inflammation in preclinical models
  • Topical peptide serums (Matrixyl, copper peptides) can stimulate collagen production in skin
  • The biological mechanisms by which these peptides affect scar formation are well-characterized

What's not yet supported:

  • No peptide has been proven in large clinical trials to reduce existing scar appearance in humans
  • The optimal peptide, concentration, timing, and application method for scar treatment are unknown
  • Whether injectable peptides produce better scar outcomes than topicals hasn't been compared
  • Long-term outcomes (years) of peptide treatment for scars haven't been studied

Practical Approaches to Using Peptides for Scars

Given the current evidence, here's a pragmatic approach:

For new scars (during healing):

  1. Allow initial wound closure to occur naturally (don't apply peptides to open wounds without medical guidance)
  2. Once the wound is closed and the scab has fallen off, begin applying a GHK-Cu serum (0.1-1%) twice daily
  3. Continue for 3-6 months — the remodeling phase where scar quality is determined
  4. Support with vitamin C (oral and topical), adequate protein, zinc, and hydration
  5. Use silicone sheets or gels simultaneously — they have the strongest clinical evidence for scar prevention and are complementary to peptide therapy

For mature scars:

  1. Topical GHK-Cu serum applied twice daily may help stimulate remodeling of existing scar tissue
  2. Matrixyl-containing products can boost collagen production in atrophic (depressed) scars
  3. Set realistic expectations — mature scars (>1 year old) respond more slowly and less completely than new scars
  4. Consider combining peptides with proven scar treatments: microneedling (which creates micro-injuries that restart remodeling), laser therapy, or chemical peels

For keloids or hypertrophic scars:

  1. Work with a dermatologist — these scars require professional management
  2. Peptides may be a useful adjunct to standard treatments (steroid injections, silicone, compression) but should not replace them
  3. The anti-inflammatory and TGF-beta-modulating properties of GHK-Cu make it the most theoretically relevant peptide for these scar types

Frequently Asked Questions

How long does it take for peptides to improve a scar?

Collagen remodeling takes months. Expect 2-3 months of consistent use before visible changes, with continued improvement over 6-12 months. New scars respond faster than mature scars. This timeline applies to topical peptides; injectable peptides (if used) may produce faster initial changes, but the underlying remodeling timeline is the same.

Can peptides remove acne scars?

Peptides can improve the appearance of atrophic (indented) acne scars by stimulating collagen production in the depressed area. Matrixyl and GHK-Cu are the most relevant peptides. However, for deep ice-pick scars, peptides alone may not be sufficient — procedures like subcision, microneedling, or laser resurfacing may be needed, with peptides used as an adjunct to support healing afterward.

Is BPC-157 effective for surgical scars?

Animal research consistently shows BPC-157 improves surgical wound healing — faster closure, better collagen organization, stronger tissue. But this hasn't been confirmed in human clinical trials specifically examining surgical scar outcomes. If you're considering BPC-157 for a surgical scar, discuss it with your surgeon before using it near a surgical site.

Can I use peptide serums on fresh wounds?

Wait until the wound is fully closed (epithelialized) before applying peptide serums. Applying products to open wounds risks introducing contamination and can interfere with natural wound closure. Once closed, topical peptides can support the remodeling phase that determines scar quality.

Which peptide is best for scars?

Based on current evidence, GHK-Cu has the most relevant data for scar improvement — it addresses collagen production, collagen organization, TGF-beta balance, inflammation, and angiogenesis simultaneously. For topical use, GHK-Cu serums are the most evidence-based choice. For research into injectable peptides, BPC-157 and TB-500 show the most promise but lack human scar-specific clinical data.

The Bottom Line

Peptides occupy a promising but incompletely validated position in scar treatment. The biology makes sense: peptides that modulate collagen organization, reduce inflammation, support angiogenesis, and regulate TGF-beta signaling address the fundamental mechanisms that determine scar quality.

GHK-Cu has the strongest case for topical scar management, with evidence for collagen remodeling, TGF-beta modulation, and gene expression changes relevant to scar quality. BPC-157 and TB-500 show impressive preclinical wound healing data but need human scar-specific trials.

The practical approach: use topical peptides as part of a comprehensive scar management strategy (alongside silicone, sun protection, and professional treatments as needed), set realistic expectations, and give the remodeling process time. Peptides aren't a magic eraser for scars — but they may meaningfully improve outcomes when used consistently and correctly.

References

  1. Gurtner, G.C., et al. "Wound repair and regeneration." Nature 453.7193 (2008): 314-321. PubMed.

  2. Bayat, A., et al. "Skin scarring." BMJ 326.7380 (2003): 88-92. BMJ.

  3. Pickart, L. "The human tri-peptide GHK and tissue remodeling." Journal of Biomaterials Science, Polymer Edition 19.8 (2008): 969-988. PubMed.

  4. Pickart, L., et al. "Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data." International Journal of Molecular Sciences 19.7 (2018): 1987. PMC.

  5. Pickart, L., and Margolina, A. "Regenerative and protective actions of the GHK-Cu peptide." International Journal of Molecular Sciences 19.7 (2018): 1987.

  6. Seiwerth, S., et al. "BPC 157's effect on healing." Journal of Physiology-Paris 93.6 (1999): 507-514. PubMed.

  7. Sosne, G., et al. "Thymosin beta 4: a potential novel therapy for neurotrophic keratopathy, dry eye, and ocular surface diseases." Vitamins and Hormones 102 (2016): 23-44. PubMed.

  8. Lee, M., and Padgett, D.E. "BPC 157 and thymosin β4 injections for knee osteoarthritis." Medical Hypotheses (2021). Retrospective study.

  9. Xue, M., and Jackson, C.J. "Extracellular matrix reorganization during wound healing and its impact on abnormal scarring." Advances in Wound Care 4.3 (2015): 119-136. PMC.

  10. Kittaka, M., et al. "Exploring the role of tripeptides in wound healing and skin regeneration." International Journal of Medical Sciences 22 (2025): 4175. MDPI.